Neuland Laboratories Limited
Neuland Laboratories Limited Fundamental Analysis
Neuland Laboratories Limited (NEULANDLAB.NS) shows weak financial fundamentals with a PE ratio of 95.48, profit margin of 11.37%, and ROE of 11.81%. The company generates $15.8B in annual revenue with weak year-over-year growth of -5.24%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 43.3/100 based on profitability, valuation, growth, and balance sheet metrics. The D grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze NEULANDLAB.NS's fundamental strength across five key dimensions:
Efficiency Score
WeakNEULANDLAB.NS struggles to generate sufficient returns from assets.
Valuation Score
ModerateNEULANDLAB.NS shows balanced valuation metrics.
Growth Score
WeakNEULANDLAB.NS faces weak or negative growth trends.
Financial Health Score
ExcellentNEULANDLAB.NS maintains a strong and stable balance sheet.
Profitability Score
WeakNEULANDLAB.NS struggles to sustain strong margins.
Key Financial Metrics
Is NEULANDLAB.NS Expensive or Cheap?
P/E Ratio
NEULANDLAB.NS trades at 95.48 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, NEULANDLAB.NS's PEG of -3.76 indicates potential undervaluation.
Price to Book
The market values Neuland Laboratories Limited at 10.56 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 49.15 times EBITDA. This signals the market has high growth expectations.
How Well Does NEULANDLAB.NS Make Money?
Net Profit Margin
For every $100 in sales, Neuland Laboratories Limited keeps $11.37 as profit after all expenses.
Operating Margin
Core operations generate 14.90 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $11.81 in profit for every $100 of shareholder equity.
ROA
Neuland Laboratories Limited generates $7.07 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Neuland Laboratories Limited generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.
Free Cash Flow
Neuland Laboratories Limited generates weak or negative free cash flow of $0.00, restricting financial flexibility.
FCF Per Share
Each share generates $0.00 in free cash annually.
FCF Yield
NEULANDLAB.NS converts 0.00% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
95.48
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-3.76
vs 25 benchmark
P/B Ratio
Price to book value ratio
10.56
vs 25 benchmark
P/S Ratio
Price to sales ratio
10.86
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.16
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.96
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.12
vs 25 benchmark
ROA
Return on assets percentage
0.07
vs 25 benchmark
ROCE
Return on capital employed
0.12
vs 25 benchmark
How NEULANDLAB.NS Stacks Against Its Sector Peers
| Metric | NEULANDLAB.NS Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 95.48 | 29.45 | Worse (Expensive) |
| ROE | 11.81% | 779.00% | Weak |
| Net Margin | 11.37% | -24936.00% (disorted) | Strong |
| Debt/Equity | 0.16 | 0.26 | Strong (Low Leverage) |
| Current Ratio | 1.96 | 4.65 | Neutral |
| ROA | 7.07% | -19344.00% (disorted) | Weak |
NEULANDLAB.NS outperforms its industry in 2 out of 6 key metrics, particularly excelling in Net Margin, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Neuland Laboratories Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
93.30%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
1504.55%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
453.49%
Industry Style: Defensive, Growth, Innovation
High Growth